M. Nanni

Publications40
h-index5
Citations320
Highly Influential Citations13
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • B. Thilaganathan
  • 469 Publications, 10,073 Citations
  • G. Sutherland
  • 625 Publications, 19,869 Citations
  • C. Nervi
  • 143 Publications, 11,958 Citations
  • H. Döhner
  • 541 Publications, 32,763 Citations
  • Publications
  • Influence
Mid‐gestational maternal cardiovascular profile in preterm and term pre‐eclampsia: a prospective study
Pre‐eclampsia (PE) is associated with maternal cardiac remodelling and biventricular diastolic dysfunction. Preterm PE alone can also be associated with severe left ventricular hypertrophy and… Expand
  • 91
  • 6
Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression.
Epigenetic modifications regulate developmental genes involved in stem cell identity and lineage choice. NFI-A is a posttranscriptional microRNA-223 (miR-223) target directing human hematopoietic… Expand
  • 128
  • 4
  • PDF
A VLBI experiment using a remote atomic clock via a coherent fibre link
We describe a VLBI experiment in which, for the first time, the clock reference is delivered from a National Metrology Institute to a radio telescope using a coherent fibre link 550 km long. The… Expand
  • 59
  • 1
Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose
Imatinib mesylate is the gold standard treatment of chronic myeloid leukaemia (CML) and 400 mg/day is considered the standard dose. Although it is generally well tolerated, some patients require… Expand
  • 14
  • 1
Is the aberrant expression of p53 by immunocytochemistry a surrogate marker of TP53 mutation and/or deletion in chronic lymphocytic leukemia?
We read with interest the article by Chang et al1 in which the aberrant expression of nuclear p53 detected by immunohistochemical analysis in 10% or more of bone marrow biopsy cells of 14 of 110… Expand
  • 4
  • 1
Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,
Abstract 3783 The achievement of Complete Cytogenetic Response (CCyR, Ph+ cells 0%) with Imatinib (IM) treatment still remains a crucial objective in Chronic Myelogenous Leukemia (CML) patients.… Expand
  • 7
Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the…
Abstract 2471 Eighty-one previously untreated CLL patients, ≤60 years, with advanced/progressive disease were included in the GIMEMA LLC0405 prospective multicenter study. Patients were stratified… Expand
  • 2
Efficacy and Safety of a First-Line Combined Therapeutic Approach for Young CLL Patients Stratified According to the Biological Prognostic Features: First Analysis of the GIMEMA Multicenter LLC0405…
It is well known that cytogenetic abnormalities, the IgVH mutational status, ZAP-70 and CD38 have a significant prognostic role in chronic lymphocytic leukemia (CLL). We therefore designed a 1 st… Expand
  • 3
Fludarabine, Cyclophosphamide and Lenalidomide (FCL) for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL): Results of the Dose-Finding Phase of the GIMEMA LLC606 Study
Abstract 1377 Targeting the CLL microenvironment with immunomodulatory agents like lenalidomide results in antileukemic activity. Addition of lenalidomide to an effective regimen such as… Expand
  • 2
Fludarabine, Ara-c, novantrone and dexamethasone plus Campath-1H for the treatment of patients with chronic lymphocytic leukemia (CLL) and adverse clinical and biologic prognostic features.
This study was conducted to determine the feasibility, safety and efficacy of the FAND plus Campath-1H combination (FAND-Cam) given to 19 previously treated CLL patients with adverse prognostic… Expand
  • 4